By Crista Casey, VP, Clinical and Regulatory Operations
Glioblastoma, also known as glioblastoma multiforme, can be very difficult to treat and a cure is often not possible. It is an aggressive type of cancer that can occur in the brain or spinal cord and it can develop at any age, but tends to occur more often in older adults. The global incidence rate of Glioblastoma is <5 per every 100,000, but rising in some locations, and has an average survival rate of 14-15 months post diagnosis. Traditionally, survival from a GBM is less than a year, and patients typically live less than six months after recurrence. The graphs below present survival and incidence.
Current data shows there are 121 products in development across 119 sponsors (commercial and academic). With a poor prognosis and limited number of therapies approved specifically for glioblastoma treatment, the indication is ripe for new therapy options. A little over 2,400 trials have been conducted in glioblastoma and 931 of those have been with marketed products. Globally, there are over 18,000 oncology trials currently enrolling or planned worldwide with just 456 enrolling or planned trials in glioblastoma.
Over the past decade, our neurologists, oncologists and clinical team experienced firsthand shifts in this research space from the use of GLIADEL Wafers, first approved devices and changes in preferred terminology e.g. glioblastoma vs glioblastoma multiforme to recent potential efficacy differences between Temodar and generics.
We understand the specific challenges in treating and researching this population and apply our medical and operational expertise when designing and implementing glioblastoma trials. Here is how we are applying our 20 years’ oncology trial experience to help find new therapies.